Intra-arterial stroke therapy: An assessment of demand and available work force

American Journal of Neuroradiology

Volumn 30, Issue 3, 2009, Pages 453-458

  Cloft, H J ^a   Rabinstein, A ^a   Lanzino, G ^a   Kallmes, D F ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

BLEEDING; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEATH; EMBOLECTOMY; HEALTH CARE AVAILABILITY; HEALTH CARE NEED; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; MEDICAL SPECIALIST; RECANALIZATION; REPERFUSION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UNITED STATES;

BRAIN ISCHEMIA; CEREBRAL ARTERIES; HUMANS; NEUROLOGY; PHYSICIANS; STROKE; THROMBOLYTIC THERAPY; UNITED STATES;

EID: 64649086708     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A1462     Document Type: Review

References (76)

1. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Qualityof Care Outcomes in Research InterdisciplinaryWorkingGroups: The American AcademyofNeurology affirms the value of this guideline as an educational tool for neurologists [published erratum appears in Circulation 2007;116:e515]. Circulation 2007;115:e478-534
2. White CJ, Cates CU, Cowley MJ, et al. Interventional stroke therapy: current state of the art and needs assessment. Catheter Cardiovasc Interv 2007;70:471-76
3. Smith WS. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol 2006;27:1177-82
4. Smith WS, SungG, Saver J, et al.Mechanicalthrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 2008;39:1205-12
5. The Interventional Management of Stroke (IMS) II Study. Stroke 2007;38:2127-35
6. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACTIIstudy:arandomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003-11
7. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005;36:1432-38
8. The IMS Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004;35:904-11
9. del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998;29:4-11
10. The NINDS Stroke Study Investigators. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med 2005;46:243-52
11. Tomsick T,Brott T,BarsanW, etal. Prognostic value ofthe hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. AJNR Am J Neuroradiol 1996;17:79-85
12. Nakajima M, Kimura K, Ogata T, et al. Relationships between angiographic findings and National Institutes of Health stroke scale score in cases of hyperacute carotid ischemic stroke. AJNR Am J Neuroradiol 2004;25:238-41
13. Fischer U, Arnold M, Nedeltchev K, et al. NIHSS score and arteriographic findings in acute ischemic stroke. Stroke 2005;36:2121-25
14. Flint AC, Duckwiler GR, Budzik RF, et al. Mechanical thrombectomy of intracranial internal carotid occlusion: pooled results of the MERCI and Multi MERCI Part I trials. Stroke 2007;38:1274-80
15. Gobin YP, Starkman S, Duckwiler GR, et al. MERCI 1: a phase 1 study of Mechanical Embolus Removal in Cerebral Ischemia. Stroke 2004;35:2848-54
16. Wolfe T, Suarez JI, Tarr RW, et al. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke. J Stroke Cerebrovasc Dis 2008;17:121-28
17. Kim D, Ford GA, Kidwell CS, et al. Intra-arterial thrombolysis for acute stroke in patients 80 and older: a comparison of results in patients younger than 80 years. AJNR Am J Neuroradiol 2007;28:159-63
18. Suarez JI, Sunshine JL, Tarr R, et al. Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intraarterial thrombolysis for acute ischemic stroke. Stroke 1999;30:2094-100
19. Barnwell SL, Clark WM, Nguyen TT, et al. Safety and efficacy of delayed intraarterial urokinase therapy with mechanical clot disruption for thromboembolic stroke. AJNR Am J Neuroradiol 1994;15:1817-22
20. Ernst R, Pancioli A, Tomsick T, et al. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke 2000;31:2552-57
21. Hill MD, Barber PA, Demchuk AM, et al. Acute intravenous-intra- arterial revascularization therapy for severe ischemic stroke. Stroke 2002;33:279-82
22. Choi JH, Bateman BT, Mangla S, et al. Endovascular recanalization therapy in acute ischemic stroke. Stroke 2006;37:419-24
23. Devlin TG, Baxter BW, Feintuch TA,etal. The Merci Retrieval System for acute stroke: the Southeast Regional Stroke Center experience. Neurocrit Care 2007;6:11-21
24. Tomsick TA. 2006: a stroke odyssey. AJNR Am J Neuroradiol 2006;27:2019-21
25. Christoforidis GA, Mohammad Y, Kehagias D, et al. Angiographic assessment of pial collaterals as a prognostic indicator following intra-arterial thrombolysis for acute ischemic stroke. AJNR Am J Neuroradiol 2005;26:1789-97
26. Schellinger PD, Fiebach JB, Jansen O, et al. Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Ann Neurol 2001;49:460-69
27. Cho AH, Sohn SI, Han MK, et al. Safety and efficacy of MRI-based thrombolysis in unclear-onset stroke. A preliminary report. Cerebrovasc Dis 2008; 25:572-79
28. Han MK,Kim SH,KoSB,etal. Combined intravenous and intraarterial revascularization therapy using MRI perfusion/diffusion mismatch selection for acute ischemic stroke at 3-6 h after symptom onset. Neurocrit Care 2008; 8:353-59
29. Schellinger PD, Thomalla G, Fiehler J, et al. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients. Stroke 2007;38:2640-45
30. Thomalla G, Schwark C, Sobesky J, et al. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 2006;37:852-58
31. Rowley HA. Extending the time window for thrombolysis: evidence from acute stroke trials. Neuroimaging Clin N Am 2005;15:575-87
32. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73
33. Derex L, Nighoghossian N, Hermier M, et al. Influence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator. J Neurol Sci 2004;225:3-9
34. Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008; 7:299-309
35. Butcher KS, Parsons M, MacGregor L, et al. Refining the perfusion-diffusion mismatch hypothesis. Stroke 2005;36:1153-59
36. Butcher K,ParsonsM, AllportL,etal. Rapid assessment of perfusion-diffusion mismatch. Stroke 2008;39:75-81
37. Lee KH, Lee SJ, Cho SJ, et al. Usefulness of triphasic perfusion computed tomography for intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke. Arch Neurol 2000;57:1000-08
38. Kloska SP, Dittrich R, Fischer T, et al. Perfusion CT in acute stroke: prediction of vessel recanalization and clinical outcome in intravenous thrombolytic therapy. Eur Radiol 2007;17:2491-98
39. MR and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE). Available at: http://clinicaltrials.gov/ct2/show/NCT00389467. Accessed June 9, 2008
40. Qureshi AI, Suri MF, Nasar A, et al. Thrombolysis for ischemic stroke in the United States: data from National Hospital Discharge Survey 1999-2001. Neurosurgery 2005;57:647-54
41. Bose A, Henkes H, Alfke K, et al. The Penumbra System: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol 2008;29:1409-13
42. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-146
43. Rosamond W, Flegal K, FridayG, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:69-171
44. ThomT,HaaseN,RosamondW,etal.Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-151
45. Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke 1998;29:415-21
46. Williams GR, Jiang JG, Matchar DB, et al. Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke 1999;30:2523-28
47. Qureshi AI, Suri MF, Nasar A, et al. Changes in cost and outcome among US patients with stroke hospitalized in 1990 to 1991 and those hospitalized in 2000 to 2001. Stroke 2007;38:2180-84
48. Schneider AT, Kissela B, Woo D, et al. Ischemic stroke subtypes: a populationbased study of incidence rates among blacks and whites. Stroke 2004; 35:1552-56
49. Petty GW, Brown RD Jr, Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 1999;30:2513-16
50. KleindorferD, Lindsell CJ, Brass L, etal. NationalUSestimatesofrecombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008;39:924-28
51. Morgenstern LB, Staub L, Chan W, et al. Improving delivery of acute stroke therapy: The TLL Temple Foundation Stroke Project. Stroke 2002;33:160-66
52. Acker JE 3rd, Pancioli AM, et al. Implementation strategies for emergency medical services within stroke systems of care: a policy statement from the American Heart Association/American Stroke Association Expert Panel on Emergency Medical Services Systems and the Stroke Council. Stroke 2007;38:3097-115
53. Lacy CR, Suh DC, Bueno M, et al. Delay in presentation and evaluation for acute stroke: Stroke Time Registry for Outcomes Knowledge and Epidemiology (S.T.R.O.K.E.). Stroke 2001;32:63-69
54. Stroke Unit Trialists' Collaboration. Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke. BMJ 1997;314:1151-59
55. Douglas VC, Tong DC, Gillum LA, et al. Do the Brain Attack Coalition's criteria for stroke centers improve care for ischemic stroke? Neurology 2005;64:422-27
56. Gropen TI, Gagliano PJ, Blake CA, et al. Quality improvement in acute stroke: the New York State Stroke Center Designation Project. Neurology 2006; 67:88-93
57. Alberts MJ, Hademenos G, Latchaw RE, et al. Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. JAMA 2000; 283:3102-09
58. Alberts MJ, Latchaw RE, Selman WR, et al. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke 2005;36:1597-616
59. The Internet Stroke CenteratWashington University InSt. Louis. Stroke Center Directory. Available at: www.strokecenter.org/strokecenters.html. Accessed May 15, 2008.
60. Silverman IE, Beland DK, Chhabra J, et al. The "drip-and- ship" approach: startingIVt-PA for acute ischemic strokeatoutside hospitals priortotransfer to a regional stroke center. Conn Med 2005;69:613-20
61. Jollis JG, Roettig ML, Aluko AO, et al. Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA 2007;298:2371-80
62. MacKenzie EJ, Hoyt DB, Sacra JC, et al. National inventory of hospital trauma centers. JAMA 2003;289:1515-22
63. Suzuki S, Saver JL, Scott P, et al. Access to intra-arterial therapies for acute ischemic stroke: an analysis of the US population. AJNR Am J Neuroradiol 2004;25:1802-06
64. Connors JJ 3rd, Sacks D, Furlan AJ, et al. Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: a joint statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, the American Societyof Neuroradiology, the Congress of Neurological Surgeons, the AANS/CNS Cerebrovascular Section, and the Society of Interventional Radiology. Neurology 2005;64:190-98
65. Higashida RT, Hopkins LN, Berenstein A, et al. Program requirements for residency/fellowshipeducationinneuroendovascular surgery/interventional neuroradiology: a special report on graduate medical education. AJNR Am J Neuroradiol 2000;21:1153-59
66. Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999; 30:2598-605
67. Jahan R, Duckwiler GR, Kidwell CS, et al. Intraarterial thrombolysis for treatment of acute stroke: experience in 26 patients with long-term follow-up. AJNR Am J Neuroradiol 1999;20:1291-99
68. Ramee SR, Subramanian R, Felberg RA, et al. Catheter-based treatment for patients with acute ischemic stroke ineligible for intravenous thrombolysis. Stroke 2004;35:109-11
69. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-87
70. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke3 to5hours after symptom onset. TheATLANTISStudy:arandomizedcontrolledtrial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282:2019-26
71. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000;283:1145-50
72. Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998;29:18-22
73. Zweifler RM, Brody ML, Graves GC, et al. Intravenous t-PA for acute ischemic stroke: therapeutic yield of a stroke code system. Neurology 1998;50:501-03
74. Grotta JC, Burgin WS, El-Mitwalli A, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 2001;58:2009-13
75. Kahn JH, Viereck J, Kase C, et al. The use of intravenous recombinant tissue plasminogen activator in acute ischemic stroke. J Emerg Med 2005;29:273-77
76. Arenillas JF, Ispierto L, Millan M, et al. Metabolic syndrome and resistance to IV thrombolysisin middle cerebral artery ischemic stroke. Neurology 2008;71: 190-95